Next-Generation Cell-Free MSC Therapy for IBD: Modular Secretomes, Dual-Axis Targeting and Multi-Route Delivery (DualSec-IBD)

Inflammatory bowel disease (IBD) remains a major unmet medical need, as current treatments primarily focus on controlling inflammation but have limited capacity to promote effective intestinal mucosal repair. The secretome of mesenchymal stromal cells (MSCs) represents a promising cell-free therapeutic alternative with both immunomodulatory and regenerative properties.